Clinical Trial

Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-11-18; most recent amendment 2026-03-06.
Trial Details
NCT Number NCT07250425
Lead Sponsor Healing Innovations
Collaborators: Kessler Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions Stroke, Neurological Diseases or Conditions, Hemiparesis;Poststroke/CVA, Gait Disorders, Neurologic, Post Stroke Fatigue, Motor Recovery, Walking Difficulty, Balance Impairment +3 more
Enrollment 20 participants
Start Date 2026-08
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-09